Misoprostol for uterine evacuation in induced abortion and pregnancy failure

References

• Herting RL, Nissen CH. Overview of misoprostol clinical experience. Dig. Dis. Sci.31(2 Suppl.), S47–S54 (1986).
   Web of Science ®Google Scholar
• Shannon CS, Winikoff B (Eds). Misoprostol: An Emerging Technology for Women’s Health. Report of a seminar. Population Council (2004).
   Google Scholar
• Borgatta L, Mullally B, Vragovic O, Gittinger E, Chen A. Misoprostol as the primary agent for medical abortion in a low-income urban setting. Contraception70(2), 121–126 (2004).
   PubMed Web of Science ®Google Scholar
• Winikoff B. Acceptability of medical abortion in early pregnancy. Fam. Plann. Perspect.27(4), 142–148 (1995).
   PubMedGoogle Scholar
• Winikoff B, Sivin I, Coyaji KJ et al. Safety, efficacy, and acceptability of medical abortion in China, Cuba, and India: a comparative trial of mifepristone–misoprostol versus surgical abortion. Am. J. Obstet. Gynecol.176(2), 431–437 (1997).
   PubMed Web of Science ®Google Scholar
• Winikoff B, Ellertson C, Elul B, Sivin I. Mifepristone Clinical Trials Group. Acceptability and feasibility of early pregnancy termination by mifepristone–misoprostol. Results of a large multicenter trial in the United States. Arch. Fam. Med.7(4), 360–366 (1998).
   PubMedGoogle Scholar
• Coyaji K, Elul B, Krishna U et al. Mifepristone abortion outside the urban research hospital setting in India. Lancet357(9250), 120–122 (2001).
   PubMed Web of Science ®Google Scholar
• Howie FL, Henshaw RC, Naji SA, Russell IT, Templeton AA. Medical abortion or vacuum aspiration? Two year follow up of a patient preference trial. Br. J. Obstet. Gynaec.104(7), 829–833 (1997).
   PubMedGoogle Scholar
• Castadot RG. Pregnancy termination: techniques, risks, and complications and their management. Fertil. Steril.45(1), 5–17 (1986).
   PubMed Web of Science ®Google Scholar
• Zieman M, Fong SK, Benowitz NL, Banskter D, Darney PD. Absorption kinetics of misoprostol with oral or vaginal administration. Obstet. Gynecol.90(1), 88–92 (1997).
   PubMed Web of Science ®Google Scholar
• Tang OS, Schweer H, Seyberth HW, Lee SW, Ho PC. Pharmacokinetics of different routes of administration of misoprostol. Human Reprod.17(2), 332–336 (2002).
   PubMed Web of Science ®Google Scholar
• Danielsson KG, Marions L, Rodriguez A, Spur BW, Wong PY, Bygdeman M. Comparison between oral and vaginal administration of misoprostol on uterine contractility. Obstet. Gynecol.93(2), 275–280 (1999).
   PubMed Web of Science ®Google Scholar
• Arvidsson C, Hellborg M, Gemzell-Danielsson K. Preference and acceptability of oral versus vaginal administration of misoprostol in medical abortion with mifepristone. Eur. J. Obstet. Gynecol. Reprod. Biol.123(1), 87–91 (2005).
   PubMed Web of Science ®Google Scholar
• Schaff EA, DiCenzo R, Fielding SL. Comparison of misoprostol plasma concentrations following buccal and sublingual administration. Contraception71(1), 22–25 (2005).
   PubMed Web of Science ®Google Scholar
• Meckstroth KR, Whitaker AK, Bertisch S, Goldberg AB, Darney PD. Misoprostol administered by epithelial routes: drug absorption and uterine response. Obstet. Gynecol.108(3), 582–590 (2006).
   PubMed Web of Science ®Google Scholar
• Csapo AI. The prospects of PGs in postconceptional therapy. Prostaglandins3(3), 245–289 (2003).
   Google Scholar
• United Nations Development Program/United Nations Fund for Population Activities/World Health Organization/World Bank Special Program of Research Development and Research Training in Human Reprod.Annual Technical Report. 1997. World Health Organization, Geneva, Switzerland (1998).
   Google Scholar
• Creinin MD, Vittinghoff E. Methotrexate and misoprostol vs. misoprostol alone for early abortion. A randomized controlled trial. JAMA272(15), 1190–1195 (1994).
   PubMed Web of Science ®Google Scholar
• Aldrich TA, Winikoff B. Does methotrexate confer a significant advantage over misoprostol alone for early medical abortion? A retrospective analysis of 8,678 cases. Brit. J. Obstet. Gynaecol. (In Press) (2007).
   Google Scholar
• Rabe T, Basse H, Thuro H, Kiessel L, Runnebaum B. Effect of the PGE1 methyl analog misoprostol on the pregnant uterus in the first trimester. Geburtshilfe Frauenheilkd.47(5), 324–331 (1987).
   PubMed Web of Science ®Google Scholar
• Norman JE, Thong KJ, Baird DT. Uterine contractility and induction of abortion in early pregnancy by misoprostol and mifepristone. Lancet338(8777), 1233–1236 (1991).
   PubMed Web of Science ®Google Scholar
• Carbonell JL, Varela L, Velazco A, Fernandez C. The use of misoprostol for termination of early pregnancy. Contraception55(3), 165–168 (1997).
   PubMed Web of Science ®Google Scholar
• Carbonell JL, Varela L, Velazco A, Fernandez C, Sanchez C. The use of misoprostol for abortion at < or = 9 weeks' gestation. Eur. J. Contracept. Reprod. Health Care2(3), 181–185 (1997).
   PubMedGoogle Scholar
• Carbonell Esteve JL, Varela L, Velazco A, Cabezas E, Tanda R, Sanchez C. Vaginal misoprostol for late first trimester abortion. Contraception57(5), 329–333 (1998).
   PubMedGoogle Scholar
• Carbonell JL, Varela L, Velazco A, Tanda R, Sanchez C. Vaginal misoprostol for abortion at 10–13 weeks' gestation. Eur. J. Contracept. Reprod. Health Care4(1), 35–40 (1999).
   PubMedGoogle Scholar
• Esteve JL, Varela L, Velazco A, Tanda R, Cabezas E, Sanchez C. Early abortion with 800 micrograms of misoprostol by the vaginal route. Contraception59(4), 219–225 (1999).
   PubMedGoogle Scholar
• Blanchard K, Shochet T, Coyaji K, Ngoc NTN, Winikoff B. Misroprostol alone for early abortion: an evaluation of seven potential regimens. Contraception72(2), 91–97 (2005).
   PubMed Web of Science ®Google Scholar
• Borgatta L, Mullally B, Vragovic O, Gittinger E, Chen A. Misoprostol as the primary agent for medical abortion in a low-income urban setting. Contraception70(2), 121–126 (2004).
   PubMed Web of Science ®Google Scholar
• Singh K, Fong YF, Dong F. A viable alternative to surgical vacuum aspiration: repeated doses of intravaginal misoprostol over 9 hours for medical termination of pregnancies up to eight weeks. Br. J. Obstet. Gynaecol.110(2), 175–180 (2003).
   Google Scholar
• Carbonell JL, Rodriguez J, Velazco A et al. Oral and vaginal misoprostol 800 µg every 8 h for early abortion. Contraception67(6), 457–462 (2003).
   PubMed Web of Science ®Google Scholar
• Jain JK, Dutton C, Harwood B, Meckstroth KR, Mishell DR Jr. A prospective randomized, double-blinded, placebo-controlled trial comparing mifepristone and vaginal misoprostol to vaginal misoprostol alone for elective termination of early pregnancy. Human Reprod.17(6), 1477–1482 (2002).
   PubMed Web of Science ®Google Scholar
• Tang OS, Miao BY, Lee SW, Ho PC. Pilot study on the use of repeated doses of sublingual misoprostol in termination of pregnancy up to 12 weeks gestation: efficacy and acceptability. Human Reprod.17(3), 654–658 (2002).
   PubMedGoogle Scholar
• Tang OS, Ho PC. Pilot study on the use of sublingual misoprostol for medical abortion. Contraception64(5), 315–317 (2001).
   PubMed Web of Science ®Google Scholar
• Zikopoulos KA, Papanikolaou EG, Kalantaridou SN et al. Early pregnancy termination with vaginal misoprostol before and after 42 days gestation. Human Reprod.17(12), 3079–3083 (2002).
   PubMedGoogle Scholar
• Carbonell JL, Velazco A, Varela L et al. Misoprostol for abortion at 9–12 weeks’ gestation in adolescents. Eur. J. Contracept. Reprod. Health Care6(1), 39–45 (2001).
   PubMedGoogle Scholar
• Carbonell JL, Rodriguez J, Aragon S et al. Vaginal misoprostol 1000 micrograms for early abortion. Contraception63(3), 131–136 (2001).
   PubMed Web of Science ®Google Scholar
• Bugalho A, Mocumbi S, Faundes A, David E. Termination of pregnancies of <6 weeks gestation with a single dose of 800 µg of vaginal misoprostol. Contraception61(1), 47–50 (2000).
   PubMed Web of Science ®Google Scholar
• Velazco A, Varela L, Tanda R et al. Misoprostol for abortion up to 9 weeks’ gestation in adolescents. Eur. J. Contracept. Reprod. Health Care5(4), 227–233 (2000).
   PubMedGoogle Scholar
• Ngai SW, Tang OS, Chan YM, Ho PC. Vaginal misoprostol alone for medical abortion up to 9 weeks of gestation: efficacy and acceptability. Human Reprod.15(5), 1159–1162 (2000).
   PubMed Web of Science ®Google Scholar
• Jain JK, Meckstroth KR, Park M, Mishell DR Jr. A comparison of tamoxifen and misoprostol to misoprostol alone for early pregnancy termination. Contraception60(6), 353–356 (1999).
   PubMedGoogle Scholar
• Jain JK, Meckstroth KR, Mishell DR Jr. Early pregnancy termination with intravaginally administered sodium chloride solution-moistened misoprostol tablets: historical comparison with mifepristone and oral misoprostol. Am. J. Obstet. Gynecol.181(6), 1386–1391 (1999).
   PubMed Web of Science ®Google Scholar
• Tang OS, Wong KS, Tang LC, Ho PC. Pilot study on the use of repeated doses of misoprostol in termination of pregnancy at less than 9 weeks of gestation. Adv. Contracept.15(3), 211–216 (1999).
   PubMedGoogle Scholar
• Ozeren M, Bilekli C, Aydemir V, Bozkaya H. Methotrexate and misoprostol used alone or in combination for early abortion. Contraception59(6), 389–394 (1999).
   PubMed Web of Science ®Google Scholar
• Bugalho A, Faundes A, Jamisse L, Usta M, Maria E, Bique C. Evaluation of the effectiveness of vaginal misoprostol to induce first trimester abortion. Contraception53(4), 244–246 (1996).
   PubMedGoogle Scholar
• Philip NM, Winikoff B, Moore K, Blumenthal P. A consensus regimen for early abortion with misoprostol. Int. J. Gynaecol. Obstet.87(3), 281–283 (2004).
   PubMed Web of Science ®Google Scholar
• Kulier R, Gulmezoglu AM, Hofmeyr GJ, Cheng LN, Campana A. Medical methods for first trimester abortion. Cochrane Database Syst. Rev.2, CD002855 (2004).
   Google Scholar
• Middleton T, Schaff E, Fielding SL et al. Randomized trial of mifepristone and buccal or vaginal misoprostol for abortion through 56 days of last menstrual period. Contraception72(5), 328–332 (2005).
   PubMed Web of Science ®Google Scholar
• Kruse B, Poppema S, Creinin MD, Paul M. Management of side effects and complications in medical abortion. Am. J. Obstet. Gynecol.183(2 Suppl.), S65–S75 (2000).
   PubMedGoogle Scholar
• Say L, Kulier R, Gulmezoglu M, Campana A. Medical versus surgical methods for first trimester termination of pregnancy. Cochrane Database Syst. Rev.1, CD003037 (2005).
   Google Scholar
• Saha S, Bal R, Ghosh S, Krishnamurthy P. Medical abortion in late second trimester – a comparative study with misoprostol through vaginal versus oral followed by vaginal route. J. Indian Med. Assoc.104(2), 81–82, 84 (2006).
   PubMedGoogle Scholar
• Liaquat NF, Javed I, Shuja S, Shoaib T, Bano K, Waheed S, Ansar A. Therapeutic termination of second trimester pregnancies with low dose misoprostol. J. Coll. Physicians Surg. Pak.16(7), 464–467 (2006).
   PubMedGoogle Scholar
• Eng NS, Guan AC. Comparative study of intravaginal misoprostol with gemeprost as an abortifacient in second trimester missed abortion. Aust N. Z. J. Obstet. Gynaecol.37(3), 331–334 (1997).
   PubMedGoogle Scholar
• Marquette GP, Skoll MA, Dontigny L. A randomized trial comparing oral misoprostol with intra-amniotic prostaglandin F2alpha for second trimester terminations.J. Obstet. Gynaecol. Can.27(11), 1013–1018 (2005).
   PubMedGoogle Scholar
• Nigam A, Singh VK, Prakash A. Vaginal vs oral misoprostol for mid-trimester abortion. Int. J. Gynaecol. Obstet.92(3), 270–271 (2006).
   PubMedGoogle Scholar
• Guix C, Palacio M, Figueras F et al. Efficacy of two regimens of misoprostol for early second-trimester pregnancy termination. Fetal Diagn. Ther.20(6), 544–548 (2005).
   PubMed Web of Science ®Google Scholar
• Borgatta L, Chen AY, Vragovic O, Stubblefield PG, Magloire CA. A randomized clinical trial of the addition of laminaria to misoprostol and hypertonic saline for second-trimester induction abortion. Contraception72(5), 358–361 (2005).
   PubMed Web of Science ®Google Scholar
• Su LL, Biswas A, Choolani M, Kalaichelvan V, Singh K. A prospective, randomized comparison of vaginal misoprostol versus intra-amniotic prostaglandins for midtrimester termination of pregnancy. Am. J. Obstet. Gynecol.193(4), 1410–1414 (2005).
   PubMedGoogle Scholar
• Nuthalapaty FS, Ramsey PS, Biggio JR, Owen J. High-dose vaginal misoprostol versus concentrated oxytocin plus low-dose vaginal misoprostol for midtrimester labor induction: a randomized trial. Am. J. Obstet. Gynecol.193(3 Pt 2), 1065–1070 (2005).
   PubMedGoogle Scholar
• Edwards RK, Sims SM. Outcomes of second-trimester pregnancy terminations with misoprostol: comparing 2 regimens. Am. J. Obstet. Gynecol.193(2), 544–548 (2005).
   PubMedGoogle Scholar
• Hidar S, Bouddebous M, Chaieb A, Jerbi M, Bibi M, Khairi H. Randomized controlled trial of vaginal misoprostol versus vaginal misoprostol and isosorbide dinitrate for termination of pregnancy at 13–29 weeks. Arch. Gynecol. Obstet.273(3), 157–160 (2005).
   PubMedGoogle Scholar
• Yilmaz B, Kelekci S, Ertas IE et al. Misoprostol moistened with acetic acid or saline for second trimester pregnancy termination: a randomized prospective double-blind trial. Human Reprod.20(11), 3067–3071 (2005).
   PubMed Web of Science ®Google Scholar
• Hamoda H, Ashok PW, Flett GM, Templeton A. A randomized trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion at 13–20 weeks gestation. Human Reprod.20(8), 2348–2354 (2005).
   PubMed Web of Science ®Google Scholar
• Caliskan E, Dilbaz S, Doger E, Ozeren S, Dilbaz B. Randomized comparison of 3 misoprostol protocols for abortion induction at 13–20 weeks of gestation. J. Reprod. Med.50(3), 173–180 (2005).
   PubMedGoogle Scholar
• Dodd J, O'Brien L, Coffey J. Misoprostol for second and third trimester termination of pregnancy: a review of practice at the Women's and Children's Hospital, Adelaide, Australia. Aust. N. Z. J. Obstet. Gynaecol.45(1), 25–29 (2005).
   PubMedGoogle Scholar
• Tang OS, Lau WN, Chan CC, Ho PC. A prospective randomised comparison of sublingual and vaginal misoprostol in second trimester termination of pregnancy. Br. J. Obstet. Gynaecol.111(9), 1001–1005 (2004).
   Google Scholar
• Ramsey PS, Savage K, Lincoln T, Owen J. Vaginal misoprostol versus concentrated oxytocin and vaginal PGE2 for second-trimester labor induction. Obstet. Gynecol.104(1), 138–145 (2004).
   PubMed Web of Science ®Google Scholar
• Carbonell JL, Rodriguez J, Delgado E et al. Vaginal misoprostol 800 microg every 12 h for second-trimester abortion. Contraception70(1), 55–60 (2004).
   PubMed Web of Science ®Google Scholar
• Langer BR, Peter C, Firtion C, David E, Haberstich R. Second and third medical termination of pregnancy with misoprostol without mifepristone. Fetal Diagn. Ther.19(3), 266–270 (2004).
   PubMed Web of Science ®Google Scholar
• Dilbaz S, Caliskan E, Dilbaz B, Kahraman BG. Frequent low-dose misoprostol for termination of second-trimester pregnancy. Eur. J. Contracept. Reprod. Health Care9(1), 11–15 (2004).
   PubMed Web of Science ®Google Scholar
• Feldman DM, Borgida AF, Rodis JF, Leo MV, Campbell WA. A randomized comparison of two regimens of misoprostol for second-trimester pregnancy termination. Am. J. Obstet. Gynecol.189(3), 710–713 (2003).
   PubMed Web of Science ®Google Scholar
• Makhlouf AM, Al-Hussaini TK, Habib DM, Makarem MH. Second-trimester pregnancy termination: comparison of three different methods. J. Obstet. Gynaecol.23(4), 407–411 (2003).
   PubMedGoogle Scholar
• Dickinson JE, Evans SF. A comparison of oral misoprostol with vaginal misoprostol administration in second-trimester pregnancy termination for fetal abnormality. Obstet. Gynecol.101(6), 1294–1299 (2003).
   PubMed Web of Science ®Google Scholar
• Mendilcioglu I, Simsek M, Seker PE, Erbay O, Zorlu CG, Trak B. Misoprostol in second and early third trimester for termination of pregnancies with fetal anomalies. Int. J. Gynaecol. Obstet.79(2), 131–135 (2002).
   PubMed Web of Science ®Google Scholar
• Bebbington MW, Kent N, Lim K et al. A randomized controlled trial comparing two protocols for the use of misoprostol in midtrimester pregnancy termination. Am. J. Obstet. Gynecol.187(4), 853–857 (2002).
   PubMed Web of Science ®Google Scholar
• Autry AM, Hayes EC, Jacobson GF, Kirby RS. A comparison of medical induction and dilation and evacuation for second-trimester abortion. Am. J. Obstet. Gynecol.187(2), 393–397 (2002).
   PubMed Web of Science ®Google Scholar
• Paz B, Ohel G, Tal T, Degani S, Sabo E, Levitan Z. Second trimester abortion by laminaria followed by vaginal misoprostol or intrauterine prostaglandin F2α: a randomized trial. Contraception65(6), 411–413 (2002).
   PubMedGoogle Scholar
• Dickinson JE, Evans SF. The optimization of intravaginal misoprostol dosing schedules in second-trimester pregnancy termination. Am. J. Obstet. Gynecol.186(3), 470–474 (2002).
   PubMed Web of Science ®Google Scholar
• Elsheikh A, Antsaklis A, Mesogitis S et al. Use of misoprostol for the termination of second trimester pregnancies. Arch. Gynecol. Obstet.265(4), 204–206 (2001).
   PubMedGoogle Scholar
• Gilbert A, Reid R. A randomised trial of oral versus vaginal administration of misoprostol for the purpose of mid-trimester termination of pregnancy. Aust. N. Z. J. Obstet. Gynaecol.41(4), 407–410 (2001).
   PubMedGoogle Scholar
• Herabutya Y, Chanrachakul B, Punyavachira P. Second trimester pregnancy termination: a comparison of 600 and 800 micrograms of intravaginal misoprostol. J. Obstet. Gynaecol. Res.27(3), 125–128 (2001).
   PubMed Web of Science ®Google Scholar
• Herabutya Y, Chanrachakul B, Punyavachira P. Vaginal misoprostol in termination of second trimester pregnancy. J. Obstet. Gynaecol. Res.26(2), 121–125 (2000).
   PubMedGoogle Scholar
• Wright-Francis DL, Raynor BD, Webb GW. Misoprostol in second trimester termination of pregnancy. Prim. Care Update Ob. Gyns.5(4), 176 (1998).
   PubMedGoogle Scholar
• Wong KS, Ngai CS, Yeo EL, Tang LC, Ho PC. A comparison of two regimens of intravaginal misoprostol for termination of second trimester pregnancy: a randomized comparative trial. Human Reprod.15(3), 709–712 (2000).
   PubMed Web of Science ®Google Scholar
• Jain JK, Kuo J, Mishell DR Jr. A comparison of two dosing regimens of intravaginal misoprostol for second-trimester pregnancy termination. Obstet. Gynecol.93(4), 571–575 (1999).
   PubMed Web of Science ®Google Scholar
• Owen J, Hauth JC. Vaginal misoprostol vs. concentrated oxytocin plus low-dose prostaglandin E2 for second trimester pregnancy termination. J. Matern. Fetal Med.8(2), 48–50 (1999).
   PubMedGoogle Scholar
• Wong KS, Ngai CS, Wong AY, Tang LC, Ho PC. Vaginal misoprostol compared with vaginal gemeprost in termination of second trimester pregnancy. A randomized trial. Contraception58(4), 207–210 (1998).
   PubMed Web of Science ®Google Scholar
• Carbonell JL, Valera L, Velazco A, Tanda R, Sanchez C. Vaginal misoprostol for early second-trimester abortion. Eur. J. Contracept. Reprod. Health Care3(2), 93–98 (1998).
   PubMedGoogle Scholar
• Dickinson JE, Godfrey M, Evans SF. Efficacy of intravaginal misoprostol in second-trimester pregnancy termination: a randomized controlled trial. J. Matern. Fetal Med.7(3), 115–119 (1998).
   PubMedGoogle Scholar
• Ghorab MN, El Helw BA. Second-trimester termination of pregnancy by extra-amniotic prostaglandin F2a or endocervical misoprostol. A comparative study. Acta Obstet. Gynecol. Scand.77(4), 429–432 (1998).
   PubMed Web of Science ®Google Scholar
• Srisomboon J, Pongpisuttinun S. Efficacy of intracervicovaginal misoprostol in second-trimester pregnancy termination: a comparison between live and dead fetuses. J. Obstet. Gynaecol. Res.24(1), 1–5 (1998).
   PubMedGoogle Scholar
• Herabutya Y, O-Prasertsawat P. Second trimester abortion using intravaginal misoprostol. Int. J. Gynaecol. Obstet.60(2), 161–165 (1998).
   PubMed Web of Science ®Google Scholar
• Nuutila M, Toivonen J, Ylikorkala O, Halmesmaki E. A comparison between two doses of intravaginal misoprostol and gemeprost for induction of second-trimester abortion. Obstet. Gynecol.90(6), 896–900 (1997).
   PubMedGoogle Scholar
• Ho PC, Ngai SW, Liu KL, Wong GC, Lee SW. Vaginal misoprostol compared with oral misoprostol in termination of second-trimester pregnancy. Obstet. Gynecol.90(5), 735–738 (1997).
   PubMed Web of Science ®Google Scholar
• Srisomboon J, Tongsong T, Pongpisuttinun S. Termination of second-trimester pregnancy with intracervicovaginal misoprostol. J. Med. Assoc. Thai.80(4), 242–246 (1997).
   PubMedGoogle Scholar
• Batioglu S, Tonguc E, Haberal A, Celikkanat H, Bagis T. Midtrimester termination of complicated pregnancy with oral misoprostol. Adv. Contracept.13(1), 55–61 (1997).
   PubMedGoogle Scholar
• Ngai SW, Tang OS, Ho PC. Prostaglandins for induction of second-trimester termination and intrauterine death. Best Pract. Res. Clin. Obstet. Gynaecol.17(5), 765–775 (2003).
   PubMed Web of Science ®Google Scholar
• Yapar EG, Senoz S, Urkutur M, Batioglu S, Gokmen O. Second trimester pregnancy termination including fetal death: comparison of five different methods. Eur. J. Obstet. Gynecol. Reprod. Biol.69(2), 97–102 (1996).
   PubMed Web of Science ®Google Scholar
• Wong KS, Ngai CS, Chan KS, Tang LC, Ho PC. Termination of second trimester pregnancy with gemeprost and misoprostol: a randomized double-blind placebo-controlled trial. Contraception54(1), 23–25 (1996).
   PubMedGoogle Scholar
• Jain JK, Mishell DR Jr. A comparison of misoprostol with and without laminaria tents for induction of second-trimester abortion. Am. J. Obstet. Gynecol.175(1), 173–177 (1996).
   PubMed Web of Science ®Google Scholar
• Bugalho A, Bique C, Pereira C, Granja AC, Bergstrom S. Uterine evacuation by vaginal misoprostol after second trimester pregnancy interruption. Acta Obstet. Gynecol. Scand.75(3), 270–273, (1996).
   PubMed Web of Science ®Google Scholar
• Jain JK, Mishell DR Jr. A comparison of intravaginal misoprostol with prostaglandin E2 for termination of second-trimester pregnancy. N. Engl. J. Med.331(5), 290–293 (1994).
   PubMed Web of Science ®Google Scholar
• Bugalho A, Bique C, Almeida L, Faundes A. The effectiveness of intravaginal misoprostol (Cytotec) in inducing abortion after eleven weeks of pregnancy. Stud. Fam. Plann.24(5), 319–323 (1993).
   PubMed Web of Science ®Google Scholar
• Baird DT. Mode of action of medical methods of abortion. J. Am. Med. Womens Assoc.55(3 Suppl.), 121–126 (2000).
   Google Scholar
• Bygdeman M, Swahn ML, Gemzell-Danielsson K, Svalander P. Mode of action of RU 486. Ann. Med.25(1), 61–64 (1993).
   PubMed Web of Science ®Google Scholar
• Bygdeman M, Gemzell DK, Marions L, Swahn M. Pregnancy termination. Steroids65(10–11), 801–805 (2000).
   PubMedGoogle Scholar
• Kovacs L, Sas M, Resch BA et al. Termination of very early pregnancy by RU 486 – an antiprogestational compound. Contraception29(5), 399–410 (1984).
   PubMed Web of Science ®Google Scholar
• Couzinet B, Le Strat N, Ulmann A, Baulieu EE, Schaison G. Termination of early pregnancy by the progesterone antagonist RU 486 (Mifepristone). N. Engl. J. Med.315(25), 1565–1570 (2002).
   Google Scholar
• Gemzell-Danielsson K, Bygdeman M, Aronsson A. Studies on uterine contractility following mifepristone and various routes of misoprostol. Contraception74(1), 31–35 (2006).
   PubMedGoogle Scholar
• Jones RK, Henshaw SK. Mifepristone for early medical abortion: experiences in France, Great Britain and Sweden. Perspect. Sex. Reprod. Health34(3), 154–161 (2002).
   PubMed Web of Science ®Google Scholar
• von Hertzen H, Honkanen H, Piaggio G et al. WHO Research Group on Post-Ovulatory Methods for Fertility Regulation. WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion. I: Efficacy. Br. J. Obstet. Gynaecol.110(9), 808–818 (2003).
   Google Scholar
• McKinnley C, Thong KJ, Baird DT. The effect of dose of mifepristone on the efficacy of medical abortion with mifepristone and misoprostol. Human Reprod.8(9), 1502–1505 (1993).
   PubMedGoogle Scholar
• Penney GC, McKessock L, Rispin R et al. An effective low cost regimen for early medical abortion. Brit. J. Fam. Plann.21, 5–6 (1995).
   Google Scholar
• Coyaji K, Elul B, Krishna U et al. Mifepristone abortion outside the urban research hospital setting in India. Lancet357(9250), 120–122 (2001).
   PubMed Web of Science ®Google Scholar
• World Health Organisation Task Force on Post-ovulatory Methods of Fertility Regulation. Comparison of two doses of mifepristone in combination with misoprostol for early medical abortion: a randomised trial. Br. J. Obstet. Gynaecol.107(4), 524–530 (2000).
   Google Scholar
• Spitz IM, Bardin CW, Benton L, Robbins A. Early pregnancy termination with mifepristone and misoprostol in the United States. N. Engl. J. Med.338(18), 1241–1247 (1998).
   PubMed Web of Science ®Google Scholar
• Ashok PW, Penney GC, Flett GM, Templeton A. An effective regimen for early medical abortion: a report of 2000 consecutive cases. Human Reprod.13(10), 2962–2965 (1998).
   PubMed Web of Science ®Google Scholar
• Peyron R, Aubeny E, Targosz V et al. Early termination of pregnancy with mifepristone (RU 486) and the orally active prostaglandin misoprostol. N. Engl. J. Med.328(21), 1509–1513 (1993).
   PubMed Web of Science ®Google Scholar
• Schaff EA, Eisinger SH, Stadalius LS, Franks P, Gore BZ, Poppema S. Low-dose mifepristone 200 mg and vaginal misoprostol for abortion. Contraception59(1), 1–6 (1999).
   PubMed Web of Science ®Google Scholar
• Shannon CS, Winikoff B, Hausknecht R et al. Multicenter trial of a simplified medical abortion regimen. Obstet. Gynecol.105(2), 345–351 (2005).
   PubMed Web of Science ®Google Scholar
• National Abortion Federation. Early Medical Abortion with Mifepristone and Other Agents. National Abortion Federation, Washington, DC, USA (2002).
   Google Scholar
• World Health Organization. Safe Abortion: Technical and Policy Guidance for Health Systems. World Health Organization, Geneva, Switzerland (2003).
   Google Scholar
• American College of Obstetricians and Gynecologists Committee on Practice Bulletins-Gynecology. ACOG practice bulletin. Clinical management guidelines for obstetricians–gynaecologists. Medical management of abortion. Obstet. Gynecol.97(Suppl. 4), 1–13 (2001).
   PubMedGoogle Scholar
• United States Food and Drug Administration approval letter for Mifeprex, dated September 28, 2000. www.fda.gov/cder/foi/appletter/2000/20687appltr.htm (Accessed 19 November 2006).
   Google Scholar
• Heikinheimo O. Clinical pharmacokinetics of mifepristone. Clin. Pharmacokinet.33(1), 7–17 (1997).
   PubMed Web of Science ®Google Scholar
• Schaff EA, Fielding SL, Westhoff C et al. Vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion: a randomized trial. JAMA284(15), 1948–1953 (2000).
   PubMed Web of Science ®Google Scholar
• Schaff EA, Fielding SL, Westhoff C. Randomized trial of oral versus vaginal misoprostol at one day after mifepristone for early medical abortion. Contraception64(2), 81–85 (2001).
   PubMed Web of Science ®Google Scholar
• Schaff E. Evidence for shortening the time interval of prostaglandin after mifepristone for medical abortion. Contraception74(1), 42–44 (2006).
   PubMed Web of Science ®Google Scholar
• Creinin MD, Schwartz JL, Pymar HC, Fink W. Efficacy of mifepristone followed on the same day by misoprostol for early termination of pregnancy: report of a randomised trial. Br. J. Obstet. Gynaecol.108(5), 469–473 (2001).
   Google Scholar
• Fox MC, Creinin MD, Harwood B. Mifepristone and vaginal misoprostol on the same day for abortion from 50 to 63 days' gestation. Contraception66(4), 225–229 (2002).
   PubMed Web of Science ®Google Scholar
• Creinin MD, Fox MC, Teal S, Chen A, Schaff EA, Meyn LA; MOD Study Trial Group. A randomized comparison of misoprostol 6 to 8 hours versus 24 hours after mifepristone for abortion. Obstet. Gynecol.103(5 Pt 1), 851–859 (2004).
   PubMed Web of Science ®Google Scholar
• Murthy AS, Creinin MD, Harwood B, Schreiber C. A pilot study of mifepristone and misoprostol administered at the same time for abortion up to 49 days gestation. Contraception71(5), 333–336 (2005).
   PubMed Web of Science ®Google Scholar
• Schreiber CA, Creinin MD, Harwood B, Murthy AS. A pilot study of mifepristone and misoprostol administered at the same time for abortion in women with gestation from 50 to 63 days. Contraception71(6), 447–450 (2005).
   PubMed Web of Science ®Google Scholar
• Kapp N, Borgatta L, Ellis SC, Stubblefield P. Simultaneous very low dose mifepristone and vaginal misoprostol for medical abortion. Contraception73(5), 525–527 (2006).
   PubMed Web of Science ®Google Scholar
• Chen AY, Mottl-Santiago J, Vragovic O, Wasserman S, Borgatta L. Bleeding after medication-induced termination of pregnancy with two dosing schedules of mifepristone and misoprostol. Contraception73(4), 415–419 (2006).
   PubMedGoogle Scholar
• Lohr PA, Reeves MF, Hayes JL, Harwood B, Creinin MD. Oral mifepristone and buccal misoprostol administered simultaneously for abortion through 63 days gestation. Contraception74(2), 181 (2006).
   Google Scholar
• Hamoda H, Ashok PW, Flett GM, Templeton A. Home self-administration of misoprostol for medical abortion up to 56 days' gestation. J. Fam. Plann. Reprod. Health Care31(3), 189–192 (2005).
   PubMedGoogle Scholar
• Tang OS, Chan CC, Ng EH, Lee SW, Ho PC. A prospective, randomized, placebo-controlled trial on the use of mifepristone with sublingual or vaginal misoprostol for medical abortions of less than 9 weeks gestation. Human Reprod.18(11), 2315–2318 (2003).
   PubMed Web of Science ®Google Scholar
• Hamoda H, Ashok PW, Dow J, Flett GMM, Templeton A. A pilot study of mifepristone in combination with sublingual or vaginal misoprostol for medical termination of pregnancy up to 63 days gestation. Contraception68(5), 335–338 (2003).
   PubMed Web of Science ®Google Scholar
• Honkanen H, Piaggio G, von Hertzen H et al. WHO Research Group on Post-Ovulatory Methods for Fertility Regulation. WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion. II: Side effects and women’s perceptions. Br. J. Obstet. Gynaecol.111(7), 715–725 (2004).
   Google Scholar
• Schaff EA, Fielding SL, Westhoff C. Randomized trial of oral versus vaginal misoprostol two days after mifepristone for early medical abortion. Contraception66(4), 247–250 (2002).
   PubMed Web of Science ®Google Scholar
• Aubeny E, Chatellier G. A randomized comparison of mifepristone and self-administered oral or vaginal misoprostol for early abortion. Eur. J. Contracept. Reprod. Health Care5(3), 171–176 (2000).
   PubMedGoogle Scholar
• Shannon C, Wiebe E, Jacot F et al. Regimens of misoprostol with mifepristone for early medical abortion: a randomised trial. Br. J. Obstet. Gynaecol.113(6), 621–628 (2006).
   Google Scholar
• Gallo MF, Cahill S, Castleman L, Mitchell EM. A systematic review of more than one dose of misoprostol after mifepristone for abortion up to 10 weeks of gestation. Contraception74(1), 36–41 (2006).
   PubMed Web of Science ®Google Scholar
• Hedley A, Ellertson C, Trussell J et al. Accounting for time: insights from a life-table analysis of the efficacy of medical abortion. Am. J. Obstet. Gynecol.191(6), 1928–1933 (2004).
   PubMedGoogle Scholar
• Ashok PW, Templeton A, Wagaarachchi PT, Flett GM. Factors affecting the outcome of early medical abortion: a review of 4132 consecutive cases. Br. J. Obstet. Gynaecol.109(11), 1281–1289 (2002).
   Google Scholar
• Aubeny E. A two-stage increase in the dose of misoprostol improves the efficacy of medical abortion with mifepristone and prostaglandins. Eur. J. Contracept. Reprod. Health Care6(1), 54–55 (2001).
   PubMed Web of Science ®Google Scholar
• Clark WH, Hassoun D, Gemzell-Danielsson K, Fiala C, Winikoff B. Home use of two doses of misoprostol after mifepristone for medical abortion: a pilot study in Sweden and France. Eur. J. Contracept. Reprod. Health Care10(3), 184–189 (2005).
   PubMed Web of Science ®Google Scholar
• Ashok PW, Flett GM, Templeton A. Termination of pregnancy at 9–13 weeks' amenorrhoea with mifepristone and misoprostol. Lancet352(9127), 542–543 (1998).
   PubMed Web of Science ®Google Scholar
• Gouk EV, Lincoln K, Khair A, Haslock J, Knight J, Cruickshank DJ. Medical termination of pregnancy at 63 to 83 days gestation. Br. J. Obstet. Gynaecol.106(6), 535–539 (1999).
   PubMedGoogle Scholar
• Cheng L. Termination of 10–16 weeks gestation with mifepristone plus misoprostol: a multi-center randomized clinical trial. Chin. J. Obstet. Gynecol.34(5), 268–71 (1999).
   Google Scholar
• Ashok PW, Kidd A, Flett GM, Fitzmaurice A, Graham W, Templeton A. A randomized comparison of medical abortion and surgical vacuum aspiration at 10–13 weeks gestation. Human Reprod.17(1), 92–98 (2002).
   PubMed Web of Science ®Google Scholar
• Hamoda H, Ashok PW, Flett GM, Templeton A. Medical abortion at 64 to 91 days of gestation: a review of 483 consecutive cases. Am. J. Obstet. Gynecol.188(5), 1315–1319 (2003).
   PubMedGoogle Scholar
• Basu R, Gundlach T, Tasker M. Mifepristone and misoprostol for medical termination of pregnancy: the effectiveness of a flexible regimen. J. Fam. Plan. Reprod. Health Care29(3), 139–141 (2003).
   PubMedGoogle Scholar
• Stewart P, Fletcher J, Sharma A. Report from the Faculty of Family Planning and Reproductive Health Care AGM, May 2003: Medical termination of pregnancy in the late first trimester. J. Fam. Plan. Reprod. Health Care29(4), 243–244 (2003).
   PubMedGoogle Scholar
• Hamoda H, Ashok PW, Flett GM, Templeton A. A randomised controlled trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion up to 13 weeks of gestation. Br. J. Obstet. Gynaecol.112(8), 1102–1108 (2005).
   Google Scholar
• Hamoda H, Ashok PW, Flett GM, Templeton A. Medical abortion at 9–13 weeks' gestation: a review of 1076 consecutive cases. Contraception71(5), 327–332 (2005).
   PubMed Web of Science ®Google Scholar
• Royal College of Obstetricians and Gynaecologists. The Care of Women Requesting Induced Abortion. RCOG Press, London, UK (2004).
   Google Scholar
• Goh SE, Thong KJ. Induction of second trimester abortion (12–20 weeks) with mifepristone and misoprostol: a review of 386 consecutive cases. Contraception73(5), 516–519 (2006).
   PubMed Web of Science ®Google Scholar
• Tang OS, Chan CC, Kan AS, Ho PC. A prospective randomized comparison of sublingual and oral misoprostol when combined with mifepristone for medical abortion at 12–20 weeks gestation. Human Reprod.20(11), 3062–3066 (2005).
   PubMed Web of Science ®Google Scholar
• Hamoda H, Ashok PW, Flett GM, Templeton A. A randomized trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion at 13–20 weeks gestation. Human Reprod.20(8), 2348–2354 (2005).
   PubMed Web of Science ®Google Scholar
• Ashok PW, Templeton A, Wagaarachchi PT, Flett GM. Midtrimester medical termination of pregnancy: a review of 1002 consecutive cases. Contraception69(1), 51–58 (2004).
   PubMed Web of Science ®Google Scholar
• Bartley J, Baird DT. A randomised study of misoprostol and gemeprost in combination with mifepristone for induction of abortion in the second trimester of pregnancy. Br. J. Obstet. Gynaecol.109(11), 1290–1294 (2002).
   Google Scholar
• le Roux PA, Pahal GS, Hoffman L, Nooh R, El-Refaey H, Rodeck CH. Second trimester termination of pregnancy for fetal anomaly or death: comparing mifepristone/misoprostol to gemeprost. Eur. J. Obstet. Gynecol. Reprod. Biol.951, 52–54 (2001).
   Google Scholar
• Ngai SW, Tang OS, Ho PC. Randomized comparison of vaginal (200 µg every 3 h) and oral (400 µg every 3 h) misoprostol when combined with mifepristone in termination of second trimester pregnancy. Human Reprod.15(10), 2205–2208 (2000).
   PubMed Web of Science ®Google Scholar
• Ashok PW, Templeton A. Nonsurgical mid-trimester termination of pregnancy: a review of 500 consecutive cases. Br. J. Obstet. Gynaecol.106(7), 706–710 (1999).
   PubMedGoogle Scholar
• Ho PC, Ngai SW, Liu KL, Wong GC, Lee SW. Vaginal misoprostol compared with oral misoprostol in termination of second-trimester pregnancy. Obstet. Gynecol.90(5), 735–738 (1997).
   PubMed Web of Science ®Google Scholar
• Jannet D, Aflak N, Abankwa A, Carbonne B, Marpeau L, Milliez J. Termination of 2nd and 3rd trimester pregnancies with mifepristone and misoprostol. Eur. J. Obstet. Gynecol. Reprod. Biol.70(2), 159–163 (1996).
   PubMedGoogle Scholar
• Ho PC, Chan YF, Lau W. Misoprostol is as effective as gemeprost in termination of second trimester pregnancy when combined with mifepristone: a randomised comparative trial. Contraception53(5), 281–283 (1996).
   PubMed Web of Science ®Google Scholar
• el-Refaey H, Templeton A. Induction of abortion in the second trimester by a combination of misoprostol and mifepristone: a randomized comparison between two misoprostol regimens. Human Reprod.10(2), 475–478 (1995).
   PubMed Web of Science ®Google Scholar
• el-Refaey H, Hinshaw K, Templeton A. The abortifacient effect of misoprostol in the second trimester. A randomized comparison with gemeprost in patients pre-treated with mifepristone (RU486). Human Reprod.8(10), 1744–1746 (1993).
   PubMedGoogle Scholar
• Webster D, Penney G, Templeton A. A comparison of 600 and 200 mg mifepristone prior to second trimester abortion with the prostaglandin misoprostol. Br. J. Obstet. Gynaecol.103(7), 706–709 (1996).
   PubMedGoogle Scholar
• Creinin MD, Vittinghoff E, Keder L, Darney PD, Tiller G. Methotrexate and misoprostol for early abortion: a multicenter trial. I. Safety and efficacy. Contraception53(6), 321–327 (1996).
   PubMed Web of Science ®Google Scholar
• Carbonell I, Esteve JL, Velazco A et al. Misoprostol 3, 4, or 5 days after methotrexate for early abortion. A randomized trial. Contraception56(3), 169–174 (1997).
   PubMed Web of Science ®Google Scholar
• Creinin MD. Medical abortion with methotrexate 75 mg intramuscularly and vaginal misoprostol. Contraception56(6), 367–371 (1997).
   PubMed Web of Science ®Google Scholar
• Creinin MD, Vittinghoff E, Schaff E, Klaisle C, Darney PD, Dean C. Medical abortion with oral methotrexate and vaginal misoprostol. Obstet. Gynecol.90(4 Pt 1), 611–616 (1997).
   PubMed Web of Science ®Google Scholar
• Wiebe ER. Abortion induced with methotrexate and misoprostol: a comparison of various protocols. Contraception55(3), 159–163 (1997).
   PubMed Web of Science ®Google Scholar
• Carbonell JL, Varela L, Velazco A, Cabezas E, Fernandez C, Sanchez C. Oral methotrexate and vaginal misoprostol for early abortion. Contraception57(2), 83–88 (1998).
   PubMed Web of Science ®Google Scholar
• Carbonell Esteve JL, Varela L, Velazco A, Tanda R, Sanchez C. 25 mg or 50 mg of oral methotrexate followed by vaginal misoprostol 7 days after for early abortion: a randomized trial. Gynecol. Obstet. Invest.47(3), 182–187 (1999).
   PubMedGoogle Scholar
• Creinin MD, Carbonell JL, Schwartz JL, Varela L, Tanda R. A randomized trial of the effect of moistening misoprostol before vaginal administration when used with methotrexate for abortion. Contraception59(1), 11–16 (1999).
   PubMed Web of Science ®Google Scholar
• Wiebe ER. Comparing abortion induced with methotrexate and misoprostol to methotrexate alone. Contraception59(1), 7–10 (1999).
   PubMedGoogle Scholar
• Borgatta L, Burnhill MS, Tyson J, Leonhardt KK, Hausknecht RU, Haskell S. Early medical abortion with methotrexate and misoprostol. Obstet. Gynecol.97(1), 11–16 (2001).
   PubMedGoogle Scholar
• Wiebe E, Dunn S, Guilbert E, Jacot F, Lugtig L. Comparison of abortions induced by methotrexate or mifepristone followed by misoprostol. Obstet. Gynecol.99(5 Pt 1), 813–819 (2002).
   PubMed Web of Science ®Google Scholar
• Creinin MD, Potter C, Holovanisin M et al. Mifepristone and misoprostol and methotrexate/misoprostol in clinical practice for abortion. Am. J. Obstet. Gynecol.188(3), 664–669 (2003).
   PubMed Web of Science ®Google Scholar
• Wiebe ER, Trouton K. Comparing vaginal and buccal misoprostol when used after methotrexate for early abortion. Contraception70(6), 463–466 (2004).
   PubMedGoogle Scholar
• Methotrexate and misoprostol for abortion. Med. Lett. Drugs Ther.38(973), 39–40 (1996).
   PubMedGoogle Scholar
• Hausknecht RU. Methotrexate and misoprostol to terminate early pregnancy. N. Engl. J. Med.333(9), 537–540 (1995).
   PubMed Web of Science ®Google Scholar
• Meckstroth KR, Darney PD. Prostaglandins for first-trimester termination. Best Pract. Res. Clin. Obstet. Gynaecol.17(5), 745–763 (2003).
   PubMed Web of Science ®Google Scholar
• Baird DT. Medical abortion in the first trimester. Best Pract. Res. Clin. Obstet. Gynaecol.16(2), 221–236 (2002).
   PubMed Web of Science ®Google Scholar
• Hausknecht R. Mifepristone and misoprostol for early medical abortion: 18 months experience in the United States. Contraception67(6), 463–465 (2003).
   PubMed Web of Science ®Google Scholar
• Henderson JT, Hwang AC, Harper CC, Steward FH. Safety of mifepristone abortions in clinical use. Contraception72(3), 175–178 (2005).
   PubMed Web of Science ®Google Scholar
• Gary MM, Harrison DJ. Analysis of severe adverse events related to the use of mifepristone as an abortifacient. Ann. Pharmacother.40(2), 191–197 (2006).
   PubMedGoogle Scholar
• Shannon C, Brothers LP, Philip NM, Winikoff B. Infection after medical abortion: a review of the literature. Contraception70(3), 183–190 (2004).
   PubMed Web of Science ®Google Scholar
• Shannon C, Brothers LP, Philip NM, Winikoff B. Ectopic pregnancy and medical abortion. Obstet. Gynecol.104(1), 161–167 (2004).
   PubMed Web of Science ®Google Scholar
• Fischer M, Bhatnagar J, Guarner J et al. Fatal toxic shock syndrome associated with Clostridium sordellii after medical abortion. N. Engl. J. Med.353(22), 2352–2360 (2005).
   PubMed Web of Science ®Google Scholar
• Sinave C, Le Templier G, Blouin D, Leveille F, Deland E. Toxic shock syndrome due to Clostridium sordellii: a dramatic postpartum and postabortion disease. Clin. Infect. Dis.35(11), 1441–1443 (2002).
   PubMed Web of Science ®Google Scholar
• Winikoff B. Clostridium sordellii infection in medical abortion. Clin. Infect. Dis.43(11), 1447–1448 (2006).
   PubMedGoogle Scholar
• Couzin J. RU-486 linked deaths to open debate about risk bacteria. Science312(5776), 986 (2006).
   PubMedGoogle Scholar
• Grimes DA. Risks of mifepristone abortion in context. Contraception71(3), 161 (2005).
   PubMed Web of Science ®Google Scholar
• Khan KS, Wojdyla D, Say L, Gulmezoglu AM, Van Look PF. WHO analysis of causes of maternal death: a systematic review. Lancet367(9516), 1066–1074 (2006).
   PubMed Web of Science ®Google Scholar
• Philip N, Shannon C, Winikoff B (Eds). Misoprostol and Teratology: Reviewing the Evidence. Population Council, New York, NY, USA (2002).
   Google Scholar
• Orioli IM, Castilla EE. Epidemiological assessment of misoprostol teratogenicity. Br. J.Obstet. Gynaecol.107(4), 519–523 (2000).
   Google Scholar
• Castilla EE, Orioli IM. Teratogenicity of misoprostol: data from the Latin-American Collaborative Study of Congenital Malformations (ECLAMC). Am. J. Med. Genet.51(2), 161–162 (1994).
   PubMedGoogle Scholar
• Addar MH. Methotrexate embryopathy in a surviving intrauterine fetus after presumed diagnosis of ectopic pregnancy: case report.J. Obstet. Gynaecol. Can.26(11), 1001–1003 (2004).
   PubMedGoogle Scholar
• Kim JO, Han JY, Choi JS et al. Oral misoprostol and uterine rupture in the first trimester of pregnancy: a case report. Reprod. Tox.20(4), 575–577 (2005).
   PubMed Web of Science ®Google Scholar
• Ramsey PS, Owen J. Midtrimester cervical ripening and labor induction. Clin. Obstet. Gynecol.43(3), 495–512 (2000).
   PubMedGoogle Scholar
• Cunningham FG, Gant NF, Leveno KJ, Gilstrap LC, Hauth JC, Wenstrom KD (Eds). Williams Obstetrics, 21st Edition. McGraw-Hill Professional, USA, 619–669 (2001).
   Google Scholar
• Gautam R, Agrawal V. Early medical termination pregnancy with methotrexate and misoprostol in lower segment cesarean section cases. J. Obstet. Gynaecol. Res.29(4), 251–256 (2003).
   PubMed Web of Science ®Google Scholar
• Xu J, Chen H, Ma T, Wu X. Termination of early pregnancy in the scarred uterus with mifepristone and misoprostol. Int. J. Gynaecol. Obstet.72(3), 245–251 (2001).
   PubMedGoogle Scholar
• Daskalakis GJ, Mesogitis SA, Papantoniou NE, Moulopoulos GG, Papapanagiotou AA, Antsaklis AJ. Misoprostol for second trimester pregnancy termination in women with prior caesarean section. Br. J. Obstet. Gynaecol.112(1), 97–99 (2005).
   Google Scholar
• Borgatta L, Burnhill M, Haskell S, Nichols M, Leonhardt K. Instituting medical abortion services: changes in outcome and acceptability related to provider experience. J. Am. Med. Womens Assoc.55(3 Suppl.), 173–176 (2000).
   Google Scholar
• Neilson JP, Hickey M, Vazquez J. Medical treatment for early fetal death (less than 24 weeks). Cochrane Database Syst. Rev.3, CD002253 (2006).
   Google Scholar
• Alberman E. Spontaneous abortion: epidemiology. In: Spontaneous Abortion: Diagnosis and Treatment. Stabile I, Grudzinskas G, Chard T (Eds). Springer-Verlag, London, UK, 9–20 (1992).
   Google Scholar
• Winikoff B. Pregnancy failure and misoprostol – time for a change. N. Engl. J. Med.353(8), 834–836 (2005).
   PubMedGoogle Scholar
• Bagratee JS, Khullar V, Regan L, Moodley J, Kagora H. A randomized controlled trial comparing medical and expectant management of first trimester miscarriage. Human Reprod.19, 266–271 (2004).
   PubMed Web of Science ®Google Scholar
• Chung TK, Lee DT, Cheung LP, Haines CJ, Chang AM. Spontaneous abortion: a randomized, controlled trial comparing surgical evacuation with conservative management using misoprostol. Fertil. Steril.71(6), 1054–1059 (1999).
   PubMedGoogle Scholar
• Creinin MD, Moyer R, Guido R. Misoprostol for medical evacuation of early pregnancy failure. Obstet. Gynecol.89, 768–772 (1997).
   PubMed Web of Science ®Google Scholar
• Herabutya Y, O-Prasertsawat P. Misoprostol in the management of missed abortion. Int. J. Gynaecol. Obstet.56(3), 263–266 (1997).
   PubMedGoogle Scholar
• Demetroulis C, Saridogan E, Kunde D, Naftalin AA. A prospective randomized control trial comparing medical and surgical treatment for early pregnancy failure. Human Reprod.16(2), 365–369 (2001).
   PubMed Web of Science ®Google Scholar
• Ngai SW, Chan YM, Tang OS, Ho PC. Vaginal misoprostol as medical treatment for first trimester spontaneous miscarriage. Human Reprod.16(7), 1493–1496 (2001).
   PubMed Web of Science ®Google Scholar
• Muffley PE, Stitely ML, Gherman RB. Early intrauterine pregnancy failure: a randomized trial of medical versus surgical treatment. Am. J. Obstet. Gynecol.187(2), 321–325 (2002).
   PubMed Web of Science ®Google Scholar
• Wood SL, Brain PH. Medical management of missed abortion: a randomized clinical trial. Obstet. Gynecol.99, 563–566 (2002).
   PubMed Web of Science ®Google Scholar
• Tang OS, Lau WN, Ng EH, Lee SW, Ho PC. A prospective randomized study to compare the use of repeated doses of vaginal and sublingual misoprostol in the management of first trimester silent miscarriages. Human Reprod.18, 176–181 (2003).
   PubMed Web of Science ®Google Scholar
• Ngoc NTN, Blum J, Westheimer E, Quan TTV, Winikoff B. Medical termination of missed abortion using misoprostol in Vietnam. Int. J. Gynecol. Obstet.87(2), 138–142 (2004).
   PubMed Web of Science ®Google Scholar
• Zhang J, Gilles JM, Barnhart K, Creinin MD, Westhoff C, Frederick MM; National Institute of Child Health Human Development (NICHD) Management of Early Pregnancy Failure Trial. A comparison of medical management with misoprostol and surgical management for early pregnancy failure. N. Engl. J. Med.353(8), 761–769 (2005).
   PubMed Web of Science ®Google Scholar
• Agostini A, Ronda I, Capelle M, Romain F, Bretelle F, Blanc B. Influence of clinical and ultrasound factors on the efficacy of misoprostol in the first trimester pregnancy failure. Fertil. Steril.84(4), 1030–1032 (2005).
   PubMedGoogle Scholar
• Tang OS, Ong CY, Tse KY, Ng EH, Lee SW, Ho PC. A randomized trial to compare the use of sublingual misoprostol with or without an additional 1 week course for the management of first trimester silent miscarriage. Human Reprod.21(1), 189–192 (2006).
   PubMedGoogle Scholar
• Nielsen S, Hahlin M, Platz-Christensen J. Randomised trial comparing expectant with medical management for first trimester miscarriages. Br. J. Obstet. Gynaecol.106(8), 804–807 (1999).
   PubMedGoogle Scholar
• Autry A, Jacobson G, Sandhu R, Isbill K. Medical management of non-viable early first trimester pregnancy. Int. J. Gynaecol. Obstet.67(1), 9–13 (1999).
   PubMed Web of Science ®Google Scholar
• Kovavisarach E, Sathapanachai U. Intravaginal 400 µg misoprostol for pregnancy termination in cases of blighted ovum: a randomised controlled trial. Aust. N. Z. J. Obstet. Gynaecol.42(2), 161–163 (2002).
   PubMedGoogle Scholar
• Al Inizi SA, Ezimokhai M. Vaginal misoprostol versus dinoprostone for the management of missed abortion. Int. J. Gynaecol. Obstet.83(1), 73–74 (2003).
   PubMedGoogle Scholar
• Gilles JM, Creinin MD, Barnhart K, Westhoff C, Frederick MM, Zhang J; National Institute of Child Health and Human Development Management of Early Pregnancy Failure Trial. A randomized trial of saline solution-moistened misoprostol versus dry misoprostol for first-trimester pregnancy failure. Am. J. Obstet. Gynecol.190(2), 389–394 (2004).
   PubMed Web of Science ®Google Scholar
• Graziosi GC, Mol BW, Reuwer PJ, Drogtrop A, Bruinse HW. Misoprostol versus curettage in women with early pregnancy failure after initial expectant management: a randomized trial. Human Reprod.19(8), 1894–1899 (2004).
   PubMed Web of Science ®Google Scholar
• Kovavisarach E, Jamnansiri C. Intravaginal misoprostol 600 µg and 800 µg for the treatment of early pregnancy failure. Int. J. Gynaecol. Obstet.90(3), 208–212 (2005).
   PubMedGoogle Scholar
• Lister MS, Shaffer LE, Bell JG, Lutter KQ, Moorma KH. Randomized, double-blind, placebo-controlled trial of vaginal misoprostol for management of early pregnancy failures. Am. J. Obstet. Gynecol.193(4), 1338–1343 (2005).
   PubMedGoogle Scholar
• Trinder J, Brocklehurst P, Porter R, Read M, Vyas S, Smith L. Management of miscarriage: expectant, medical, or surgical? Results of randomised controlled trial (miscarriage treatment (MIST) trial). Brit. Med. J.332(7552), 1235–1240 (2006).
   PubMed Web of Science ®Google Scholar
• Henshaw RC, Cooper K, El-Refaey H, Smith NC, Templeton AA. Medical management of miscarriage: non-surgical uterine evacuation of incomplete and inevitable spontaneous abortion. Brit. Med. J.306, 894–895 (1993).
   PubMed Web of Science ®Google Scholar
• Chung TK, Cheung LP, Leung TY, Haines CJ, Chang AM. Misoprostol in the management of spontaneous abortion. Brit. J. Obstet. Gynecol.102, 832–835 (1995).
   PubMedGoogle Scholar
• de Jonge ETM, Makin JD, Manefeldt E, De Wet GH, Pattinson RC. Randomised clinical trial of medical evacuation and surgical curettage for incomplete miscarriage. Brit. Med. J.311(9), 662 (1995).
   PubMed Web of Science ®Google Scholar
• Pandian Z, Ashok P, Templeton A. The treatment of incomplete miscarriage with oral misoprostol. Brit. J. Obstet. Gynecol.108(2), 213–214 (2001).
   Google Scholar
• Pang MW, Lee TS, Chung TK. Incomplete miscarriage: a randomized controlled trial comparing oral with vaginal misoprostol for medical evacuation. Human Reprod.16(11), 2283–2287 (2001).
   PubMedGoogle Scholar
• Sahin HG, Sahin HA, Kocer M. Randomized outpatient clinical trial of medical evacuation and surgical curettage in incomplete miscarriage. Eur. J. Contracept. Reprod. Health Care6(3), 141–144 (2001).
   PubMed Web of Science ®Google Scholar
• Gronlund AL, Clevin L, Anderson B, Palmgren N, Lidegaard A. Spontaneous abortion: expectant management, medical treatment or surgical evacuation. Acta Obstet. Gynecol. Scand.81(8), 781–782 (2002).
   PubMedGoogle Scholar
• Blanchard K, Taneepanichskul S, Kiriwat O et al. Two regimens of misoprostol for treatment of incomplete abortion. Obstet. Gynecol.103, 860–865 (2004).
   PubMedGoogle Scholar
• Moodliar S, Bagrattee JS, Moodley J. Medical vs. surgical evacuation of first-trimester spontaneous abortion. Int. J. Gynecol. Obstet.91, 21–26 (2005).
   PubMed Web of Science ®Google Scholar
• Ngoc NTN, Blum J, Durocher J, Quan TTV, Winikoff B. Medical management of incomplete abortion using 600 versus 1200 µg of misoprostol. Contraception72(6), 438–442 (2005).
   PubMedGoogle Scholar
• Weeks A, Alia G, Blum J et al. A randomised trial of oral misoprostol versus manual vacuum aspiration for the treatment of incomplete abortion in Kampala, Uganda. Obstet. Gynecol.106(3), 540–547 (2005).
   PubMed Web of Science ®Google Scholar
• Shwekerela B, Kalumuna R, Kipingili R et al. Misoprostol for treatment of incomplete abortion at the regional hospital level: results from Tanzania. Brit. J. Obstet. Gynecol. (2006) (In press).
   Google Scholar
• Chung T, Leung P, Cheung LP, Haines C, Chang AM. A medical approach to management of spontaneous abortion using misoprostol. Extending misoprostol treatment to a maximum of 48 hours can further improve evacuation of retained products of conception in spontaneous abortion. Acta Obstet. Gynecol. Scand.76(3), 248–251 (1997).
   PubMed Web of Science ®Google Scholar
• Shelley JM, Healy D, Grover S. A randomised trial of surgical, medical and expectant management of first trimester spontaneous miscarriage. Aust. N. Z. J. Obstet. Gynaecol.45(2), 122–127 (2005).
   PubMedGoogle Scholar
• Shulman LP, Lipscomb GH, Ling FW. Management of abnormal pregnancies. In: A Clinician’s Guide to Medical and Surgical Abortion. Paul M, Lichtenberg ES, Borgatta L, Grimes DA, Stubblefield PG (Eds). WB Saunders Company, CA, USA (1999).
   Google Scholar
• Romero R, Copel JA, Hobbins JC. Intrauterine fetal demise and hemostatic failure: the fetal death syndrome. Clin. Obstet. Gynecol.28(1), 24–31 (1985).
   PubMed Web of Science ®Google Scholar
• Jain JK, Mishell DR Jr. A comparison of misoprostol with and without laminaria tents for induction of second-trimester abortion. Am. J. Obstet. Gynecol.175(1), 173–177 (1996).
   PubMed Web of Science ®Google Scholar
• Jain JK, Mishell DR Jr. A comparison of intravaginal misoprostol with prostaglandin E2 for termination of second-trimester pregnancy. N. Engl. J. Med.331(5), 290–293 (1994).
   PubMed Web of Science ®Google Scholar
• Bugalho A, Bique C, Machungo F, Bergstrom S. Vaginal misoprostol as an alternative to oxytocin for induction of labor in women with late fetal death. Acta Obstet. Gynecol. Scand.74(3), 194–198 (1995).
   PubMed Web of Science ®Google Scholar
• Fletcher HM, Wharf G, Simeon D et al. Induction of labour with intravaginal misoprostol versus dinoprostone in intrauterine death: a retrospective study. J. Obstet. Gynaecol.16, 155–158 (1996).
   Google Scholar
• Makhlouf AM, Al-Hussaini TK, Habib DM, Makarem MH. Second-trimester pregnancy termination: comparison of three different methods. J. Obstet. Gynaecol.23(4), 407–411 (2003).
   PubMedGoogle Scholar
• Mendilcioglu I, Simsek M, Seker PE, Erbay O, Zorlu CG, Trak B. Misoprostol in second and early third trimester for termination of pregnancies with fetal anomalies. Int. J. Gynaecol. Obstet.79(2), 131–135 (2002).
   PubMed Web of Science ®Google Scholar
• Yapar EG, Senoz S, Urkutur M, Batioglu S, Gokmen O. Second trimester pregnancy termination including fetal death: comparison of five different methods. Eur. J. Obstet. Gynecol. Reprod. Biol.69(2), 97–102 (1996).
   PubMed Web of Science ®Google Scholar
• Ramsey PS, Savage K, Lincoln T, Owen J. Vaginal misoprostol versus concentrated oxytocin and vaginal PGE2 for second-trimester labor induction. Obstet. Gynecol.104(1), 138–145 (2004).
   PubMed Web of Science ®Google Scholar
• De Heus R, Graziosi GC, Christiaens GC, Bruinse HW, Mol BW. Medical management for termination of second and third trimester pregnancies: a comparison of strategies. Eur. J. Obstet. Gynecol. Reprod. Biol.116(1), 16–21 (2004).
   PubMedGoogle Scholar
• Ramin KD, Ogburn PL, Danilenko DR, Ramsey PS. High-dose oral misoprostol for mid-trimester pregnancy interruption. Gynecol. Obstet. Invest.54(3), 176–179 (2002).
   PubMedGoogle Scholar
• Eng NS, Guan AC. Comparative study of intravaginal misoprostol with gemeprost as an abortifacient in second trimester missed abortion. Aust. N. Z. J. Obstet. Gynaecol.37(3), 331–334 (1997).
   PubMedGoogle Scholar
• Dickinson JE, Godfrey M, Evans SF. Efficacy of intravaginal misoprostol in second-trimester pregnancy termination: a randomized controlled trial. J. Matern. Fetal Med.7(3), 115–119 (1998).
   PubMedGoogle Scholar
• Owen J, Hauth JC. Vaginal misoprostol vs concentrated oxytocin plus low-dose prostaglandin E2 for second trimester pregnancy termination. J. Matern. Fetal Med.8(2), 48–50 (1999).
   PubMedGoogle Scholar
• Nuutila M, Toivonen J, Ylikorkala O, Halmesmaki E. A comparison between two doses of intravaginal misoprostol and gemeprost for induction of second-trimester abortion. Obstet. Gynecol.90(6), 896–900 (1997).
   PubMedGoogle Scholar
• Lauersen NH, Cederqvist LL, Wilson KH. Management of intrauterine fetal death with prostaglandin E2 vaginal suppositories. Am. J. Obstet. Gynecol.137(7), 753–757 (1980).
   PubMedGoogle Scholar
• Niromanesh S, Hashemi-Fesharaki M, Mosavi-Jarrahi A. Second trimester abortion using intravaginal misoprostol. Int. J. Gynaecol. Obstet.89(3), 276–277 (2005).
   PubMedGoogle Scholar
• Wagaarachchi PT, Ashok PW, Narvekar NN, Smith NC, Templeton A. Medical management of late intrauterine death using a combination of mifepristone and misoprostol. Brit. J. Obstet. Gynecol.109(4), 443–447 (2002).
   Google Scholar
• Bique C, Bugalho A, Bergstrom S. Labor induction by vaginal misoprostol in grand multiparous women. Acta Obstet. Gynecol. Scand.78(3), 198–201 (1999).
   PubMedGoogle Scholar
• Bugalho A, Bique C, Machungo F, Faaundes A. Induction of labor with intravaginal misoprostol in intrauterine fetal death. Am. J. Obstet. Gynecol.171(2), 538–541 (1994).
   PubMedGoogle Scholar
• Chittacharoen A, Herabutya Y, Punyavachira P. A randomized trial of oral and vaginal misoprostol to manage delivery in cases of fetal death. Obstet. Gynecol.101(1), 70–73 (2003).
   PubMed Web of Science ®Google Scholar
• Draycott T, Hawkes N, Read MD. Induction of labour with vaginal misoprostol after intrauterine death from 24 weeks gestation. J. Obstet. Gynaecol.16, 517–518 (1996).
   Google Scholar
• Merrell DA, Koch MA. Induction of labour with intravaginal misoprostol in the second and third trimesters of pregnancy. S. Afr. Med. J.85(10 Suppl.), 1088–1090 (1995).
   PubMedGoogle Scholar
• Srisomboon J, Pongpisuttinun S. Efficacy of intracervicovaginal misoprostol in second-trimester pregnancy termination: a comparison between live and dead fetuses. J. Obstet. Gynaecol. Res.24(1), 1–5 (1998).
   PubMedGoogle Scholar
• Fadalla FA, Mirghani OA, Adam I. Oral misoprostol vs. vaginal misoprostol for termination of pregnancy with intrauterine fetal demise in the second-trimester. Int. J. Gynaecol. Obstet.86(1), 52–53 (2004).
   PubMedGoogle Scholar
• Pongsatha S, Tongsong T. Therapeutic termination of second trimester pregnancies with intrauterine fetal death with 400 micrograms of oral misoprostol. J. Obstet. Gynaecol. Res.30(3), 217–220 (2004).
   PubMedGoogle Scholar
• Feldman DM, Borgida AF, Rodis JF, Leo MV, Campbell WA. A randomized comparison of two regimens of misoprostol for second-trimester pregnancy termination. Am. J. Obstet. Gynecol.189(3), 710–713 (2003).
   PubMed Web of Science ®Google Scholar
• Fairley TE, Mackenzie M, Owen P, Mackenzie F. Management of late intrauterine death using a combination of mifepristone and misoprostol – experience of two regimens. Eur. J. Obstet. Gynecol. Reprod. Biol.118(1), 28–31 (2005).
   PubMedGoogle Scholar
• Dickinson JE, Evans SF. The optimization of intravaginal misoprostol dosing schedules in second-trimester pregnancy termination. Am. J. Obstet. Gynecol.186(3), 470–474 (2002).
   PubMed Web of Science ®Google Scholar
• Jain JK, Kuo J, Mishell DR Jr. A comparison of two dosing regimens of intravaginal misoprostol for second-trimester pregnancy termination. Obstet. Gynecol.93(4), 571–575 (1999).
   PubMed Web of Science ®Google Scholar
• Dodd J, O'Brien L, Coffey J. Misoprostol for second and third trimester termination of pregnancy: a review of practice at the Women's and Children's Hospital, Adelaide, Australia. Aust. N. Z. J. Obstet. Gynaecol.45(1), 25–29 (2005).
   PubMedGoogle Scholar
• Yilmaz B, Kelekci S, Ertas IE et al. Misoprostol moistened with acetic acid or saline for second trimester pregnancy termination: a randomized prospective double-blind trial. Human Reprod.20(11), 3067–3071 (2005).
   PubMed Web of Science ®Google Scholar
• Edwards RK, Sims SM. Outcomes of second-trimester pregnancy terminations with misoprostol: comparing two regimens. Am. J. Obstet. Gynecol.193(2), 544–548; author reply 548 (2005).
   PubMedGoogle Scholar
• Jannet D, Aflak N, Abankwa A, Carbonne B, Marpeau L, Milliez J. Termination of 2nd and 3rd trimester pregnancies with mifepristone and misoprostol. Eur. J. Obstet. Gynecol. Reprod. Biol.70(2), 159–163 (1996).
   PubMedGoogle Scholar
• Sanchez-Ramos L, Kaunitz AM, Delke I. Labor induction with 25 µg versus 50 µg intravaginal misoprostol: a systematic review. Obstet. Gynecol.99(1), 145–151 (2002).
   PubMed Web of Science ®Google Scholar
• Goldberg AB, Wing DA. Induction of labor: the misoprostol controversy. J. Midwifery Womens Health48(4), 244–248 (2003).
   PubMedGoogle Scholar
• Wing DA, Lyons Gaffaney CA. Vaginal misoprostol administration for cervical ripening and labor induction. Clin. Obstet. Gynecol.49(3), 627–641 (2006).
   PubMed Web of Science ®Google Scholar
• Daskalakis GJ, Mesogitis SA, Papantoniou NE, Moulopoulos GG, Papapanagiotou AA, Antsaklis AJ. Misoprostol for second trimester pregnancy termination in women with prior caesarean section. Brit. J. Obstet. Gynecol.112(1), 97–99 (2005).
   Google Scholar
• Pongsatha S, Tongsong T. Misoprostol for second trimester termination of pregnancies with prior low transverse cesarean section. Int. J. Gynaecol. Obstet.80(1), 61–62 (2003).
   PubMed Web of Science ®Google Scholar
• Dickinson JE, Evans SF. A comparison of oral misoprostol with vaginal misoprostol administration in second-trimester pregnancy termination for fetal abnormality. Obstet. Gynecol.101(6), 1294–1299 (2003).
   PubMed Web of Science ®Google Scholar
• Dickinson JE. Misoprostol for second-trimester pregnancy termination in women with a prior cesarean delivery. Obstet. Gynecol.105(2), 352–356 (2005).
   PubMed Web of Science ®Google Scholar
• Bartley J, Baird DT. A randomised study of misoprostol and gemeprost in combination with mifepristone for induction of abortion in the second trimester of pregnancy. Brit. J. Obstet. Gynecol.109(11), 1290–1294 (2002).
   Google Scholar
• Khabbaz AY, Usta IM, El-Hajj MI, Abu-Musa A, Seoud M, Nassar AH. Rupture of an unscarred uterus with misoprostol induction: case report and review of the literature. J. Matern. Fetal Med.10(2), 141–145 (2001).
   PubMedGoogle Scholar
• Nayki U, Taner CE, Mizrak T, Nayki C, Derin G. Uterine rupture during second trimester abortion with misoprostol. Fetal Diagn. Ther.20(5), 469–471 (2005).
   PubMedGoogle Scholar
• Daskalakis G, Papantoniou N, Mesogitis S, Papageorgiou J, Antsaklis A. Sonographic findings and surgical management of a uterine rupture associated with the use of misoprostol during second-trimester abortion. J. Ultrasound Med.24(11), 1565–1568 (2005).
   PubMedGoogle Scholar
• Al-Hussaini TK. Uterine rupture in second trimester abortion in a grand multiparous woman. A complication of misoprostol and oxytocin. Eur. J. Obstet. Gynecol. Reprod. Biol.96(2), 218–219 (2001).
   PubMed Web of Science ®Google Scholar
• Letourneur B, Parant O, Tofani V, Berrebi A. Uterine rupture on unscarred uterus following labor induction for 2(nd) trimester termination of pregnancy with oral misoprostol: conservative management. J. Gynecol. Obstet. Biol. Reprod. (Paris)31(4), 371–373 (2002).
   Google Scholar
• Phillips K, Berry C, Mathers AM. Uterine rupture during second trimester termination of pregnancy using mifepristone and a prostaglandin. Eur. J. Obstet. Gynecol. Reprod. Biol.65, 175–176 (1996).
   PubMedGoogle Scholar
• Bagga R, Chaudhary N, Kalra J. Rupture in an unscarred uterus during second trimester pregnancy termination with mifepristone and misoprostol. Int. J. Gynaecol. Obstet.87(1), 42–43 (2004).
   PubMed Web of Science ®Google Scholar
• Samuels TA, Awonuga A. Second-trimester rudimentary uterine horn pregnancy: rupture after labor induction with misoprostol. Obstet. Gynecol.106(5 Pt 2), 1160–1162 (2005).
   PubMedGoogle Scholar
• Mathews JE, Mathai M, George A. Uterine rupture in a multiparous woman during labor induction with oral misoprostol. Int. J. Gynaecol. Obstet.68(1), 43–44 (2000).
   PubMedGoogle Scholar
• Bennett BB. Uterine rupture during induction of labor at term with intravaginal misoprostol. Obstet. Gynecol.89(5 Pt 2), 832–833 (1997).
   PubMed Web of Science ®Google Scholar
• Daisley H Jr. Maternal mortality following the use of misoprostol. Med. Sci. Law40(1), 78–82 (2000).
   PubMedGoogle Scholar
• Wing DA, Lovett K, Paul RH. Disruption of prior uterine incision following misoprostol for labor induction in women with previous cesarean delivery. Obstet. Gynecol.91(5 Pt 2), 828–830 (1998).
   PubMed Web of Science ®Google Scholar
• Sciscione AC, Nguyen L, Manley JS, Shlossman PA, Colmorgen GH. Uterine rupture during preinduction cervical ripening with misoprostol in a patient with a previous Caesarean delivery. Aust. N. Z. J. Obstet. Gynaecol.38(1), 96–97 (1998).
   PubMedGoogle Scholar
• Blanchette HA, Nayak S, Erasmus S. Comparison of the safety and efficacy of intravaginal misoprostol (prostaglandin E1) with those of dinoprostone (prostaglandin E2) for cervical ripening and induction of labor in a community hospital. Am. J. Obstet. Gynecol.180(6 Pt 1), 1551–1559 (1999).
   PubMedGoogle Scholar
• Plaut MM, Schwartz ML, Lubarsky SL. Uterine rupture associated with the use of misoprostol in the gravid patient with a previous cesarean section. Am. J. Obstet. Gynecol.180(6 Pt 1), 1535–1542 (1999).
   PubMed Web of Science ®Google Scholar
• Mazzone ME, Woolever J. Uterine rupture in a patient with an unscarred uterus: a case study. Wisconsin Med. J.105(2), 64–66 (2006).
   Google Scholar
• Bugalho A, Bique C, Machungo F, Bergstrom S. A comparative study of vaginal misoprostol and intravenous oxytocin for induction of labour. Gynecol. Obstet. Invest.39(4), 252–256 (1995).
   PubMedGoogle Scholar
• Ezegwui HU. Uterine rupture in a primigravida when misoprostol was used for induction of labour and subsequent successful pregnancy outcome. Obstet. Gynaecol.26(2), 160–161 (2006).
   Google Scholar
• Selo-Ojeme DO, Ayida GA. Uterine rupture after a single vaginal 2 mg prostaglandin gel application in a primiparous woman. Eur. J. Obstet. Gynecol. Reprod. Biol.101(1), 87–88 (2002).
   PubMedGoogle Scholar
• Bahar AM, Archibong EI, Zaki ZM, Mahfouz AA. Induction of labour using low and high dose regimens of prostaglandin E2 vaginal tablets. East Afr. Med. J.80(1), 51–55 (2003).
   PubMedGoogle Scholar
• Siddiqui M, Ranasinghe JS. Spontaneous rupture of uterus. J. Clin. Anesth.14(5), 368–370 (2002).
   PubMedGoogle Scholar
• Miles AL, Monga M, Waller DK, Dande D, Pschirrer ER. Risk factors for symptomatic uterine rupture during a trial of labor: the 1990s. Am. J. Perinatol.17(7), 385–389 (2000).
   PubMed Web of Science ®Google Scholar